What does GHRP-2 stack well with?

For body composition / training protocols, GHRP-2 pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from GHRP-2's primary mechanism (Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs), producing additive or synergistic effects rather than receptor competition.

What route should I use for GHRP-2?

GHRP-2 is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

How long until I see results from GHRP-2?

Acute effects from GHRP-2 appear within hours of dosing for receptor-level changes. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What are the safety considerations for GHRP-2?

More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy. For anabolic and recovery use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. GHRP-2's ~15-60 min pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

How does GHRP-2's half-life affect dosing?

GHRP-2 has a plasma half-life of ~15-60 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-3x daily subq dosing at 100-300 mcg per dose explains the typical onset timeline for anabolic and recovery endpoints.

Home/ Compounds/ GHRP-2

GHRP-2

Body Composition

For the body-composition and physique community, GHRP-2 is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin.. The ~15-60 min pharmacokinetic profile determines training-day versus rest-day dosing, while the subq administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

Body RecompositionEnduranceInjury RecoveryWorkout RecoveryTendon Repair

Key Takeaways

Body composition lens: response to GHRP-2 is proportional to training stimulus and nutritional adequacy.
Mechanism: Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs.
Body composition dose: 100-300 mcg 2-3x daily subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by GHRP-2.

Anabolic substrate and protein synthesis

GHRP-2's relevance to body composition depends on where in the anabolic cascade it acts. It acts on adjacent rather than directly anabolic pathways, but the contribution to recovery, connective tissue, and inflammatory tone produces measurable body-composition effects in trained users. The downstream effect on body composition is dose- and training-dependent.

Hyperplasia and structural adaptation

Where GHRP-2 demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. GHRP-2 with a ~15-60 min half-life of ~15-60 min is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Body Composition / Training Applications

Strength

The body composition community converges on GHRP-2 for strength with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Training Performance

For training performance, GHRP-2 integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Workout Recovery

Workout Recovery responds to GHRP-2 with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Muscle Endurance

The body composition community converges on GHRP-2 for muscle endurance with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-300 mcg	4–6 weeks initial cycle
Body Composition focus	SubQ	100-300 mcg	2-3x daily SubQ
Maintenance phase	SubQ	70-300 mcg	Ongoing with periodic pauses

Dose timing for GHRP-2 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

GHRP-2 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

GHRP-2 + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with GHRP-2's mechanism in body composition / training protocols.
GHRP-2 + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with GHRP-2's mechanism in body composition / training protocols.
GHRP-2 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with GHRP-2's mechanism in body composition / training protocols.
GHRP-2 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with GHRP-2's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Approved in Japan for GH stimulation testing only

More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy.

Lens-specific safety considerations for body composition / training use of GHRP-2: More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

GHRP-2 mechanism of GH secretion

PMID 12679487

Supporting

Pralmorelin / GHRP-2 clinical use

PMID 10221681

GHRP-2 vs Related Peptides

Compound	Profile	Onset	Best For
GHRP-2	Growth hormone releasing peptide	~15-60 min	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Should I cycle GHRP-2?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

Best stack pairing for lean mass?

The canonical lean mass stack pairs GHRP-2 with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

Can I use GHRP-2 alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

How should GHRP-2 be stored and reconstituted?

Lyophilised GHRP-2 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What is the regulatory status of GHRP-2?

GHRP-2 regulatory status: Approved in Japan for GH stimulation testing only in the United States; WADA status banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Clinical Protocol

Start a GHRP-2 Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified GHRP-2 and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 817 Da
Sequence length: 6 aa
Half-life: ~15-60 min
WADA: Banned (S2)
FDA: Approved in Japan for GH stimulation testing only

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHRP-2 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for GHRP-2

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised